Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326846 | 0.88 | CHRM4 (0.55) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL12639817 | 0.86 | GPR119 (0.56) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL2226561 | 0.83 | NOTUM (0.56) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL12099334 | 0.81 | GPR119 (0.55) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL3857665 | 0.80 | USP30 (0.60) | CHRM4GPR119PANK3DPP4TACR3 | |
| SCHEMBL26292225 | 0.79 | PANK3 (0.59) | CHRM4GPR119PANK3 | |
| SCHEMBL16718831 | 0.79 | JAK2 (0.54) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL13622620 | 0.79 | KCNH2 (0.55) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL31289277 | 0.79 | GPR119 (0.56) | CHRM4GPR119PANK3DPP4JAK2 | |
| SCHEMBL2225455 | 0.79 | PDK1 (0.54) | CHRM4GPR119PANK3DPP4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | CHRM4 1153/4885GPR119 1784/4885PANK3 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.